Review article: emerging drug therapies in inflammatory bowel disease
- 15 February 2022
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 55 (7) , 789-804
Abstract
Summary: Background: The landscape of inflammatory bowel disease (IBD) treatment is rapidly expanding with the development of new therapeutic options.Aim: To review the mechanisms of action and the available clinical trial data on emerging drug therapies for IBD.Methods: Pubmed, Medline and Cochrane databases were queried up to July 2021 using keywords “inflammatory bowel disease,” “IBD,” “Crohn’s disease,” “ulcerative colitis” and “trial,” “phase” and “study.” In addition, we manually reviewed the grey literature including clinical trial registries and abstracts from major gastroenterology conferences in 2020 and 2021 to include pertinent information.Results: In ulcerative colitis (UC), phase 2b and/or phase 3 studies met primary endpoints for S1P receptor agonists (estrasimod, ozanimod), anti‐IL‐23 agent (mirikizumab), anti‐lymphocyte trafficking agents (ontamalimab, subcutaneous vedolizumab), JAK inhibitors (upadacitinib, filgotinib) and TLR9 agonist (cobitolimod). In Crohn’s disease (CD), anti‐IL‐23 agents (risankizumab, mirikizumab, guselkumab), JAK inhibitors (upadacitinib, filgotinib) and anti‐lymphocyte trafficking agents (ontamalimab, etrolizumab) met primary endpoints in randomised controlled clinical trials.Conclusion: Several new IBD drug therapies have positive efficacy and safety data in early clinical trials, and there are several drugs in the therapeutic pipeline. As more treatments for CD and UC are approved for clinical use, research to assess predictors of response to therapy and head‐to‐head trials is needed to inform providers on how to best position therapeutic options for patients with IBD.Keywords
This publication has 32 references indexed in Scilit:
- Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a StudyGastroenterology, 2017
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2017
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s DiseaseNew England Journal of Medicine, 2016
- Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative ColitisGastroenterology, 2015
- Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseNew England Journal of Medicine, 2013
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2013
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE TrialGastroenterology, 2007
- A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease GeneScience, 2006